Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study unconfirmed

Story checked

Experimental treatment selectively reduces harmful protein in lab models of rare inherited brain disorder (opens in a new tab)

medicalxpress.com · 2026-10-21

Short answerEvidenceSource

Short answer

Source study unconfirmed

Study not confirmed.

The search did not establish a source study for this article. Its claims remain unverified; this does not mean they are incorrect.

15 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1

The story

Experimental treatment selectively reduces harmful protein in lab models of rare inherited brain disorder

medicalxpress.com · 2026-10-21

The story’s checkable claims.

Read the original story (opens in a new tab)
2

NewsLink checks it

No single source study could be confirmed.

The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.

View article claims
3

Search result

Source study unconfirmed.

The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.

Source paper

Source layer

The paper behind the story

The source record for this check.

The research anchor for the report.

The literature search

15 candidate papers

Studies identified during the search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 11 more search results
Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Claim 1 of 6Not checkedResearchers from DZNE and the Hertie Institute for Clinical Brain Research, with collaborators from Bonn, London and Portugal, developed and tested in human neurons cultured in the lab a new approach for treating spinocerebellar ataxia type 3 (SCA3).View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 6Not checkedThe findings, published in Science Translational Medicine, could pave the way for a therapy that alleviates symptoms and slows progression of the rare inherited brain disorder.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 6Not checkedThe researchers designed antisense oligonucleotides to specifically reduce harmful ataxin-3 while largely preserving the normal protein.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 6Not checkedThe most effective substance tested reduced toxic ataxin-3 by approximately 90% while the normal protein was largely preserved.View evidenceHide evidence

As statedapproximately 90%

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 5 of 6Not checkedBy analyzing the genomes of 79 individuals with SCA3, the researchers identified single-nucleotide polymorphisms that helped the ASOs preferentially target the disease-causing gene copy.View evidenceHide evidence

As stated79 individuals

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 6 of 6Not checkedThe team says the next steps are further optimization and additional laboratory studies before any possible human clinical trials.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

PubMed, Europe PMC, Crossref · 15 candidate papers

Candidate

Faculty Opinions recommendation of Antisense oligonucleotide therapy for spinocerebellar ataxia type 2.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · 2018 · Crossref

Source (opens in a new tab)
Candidate

Faculty Opinions recommendation of Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · 2019 · Crossref

Source (opens in a new tab)

Explore all search results